Annual report pursuant to Section 13 and 15(d)

Royalty and other income

Royalty and other income
12 Months Ended
Jul. 31, 2017
Royalty And Other Income [Abstract]  
Royalty And Other Income [Text Block]

Note 12 - Royalty and other income

The Company has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly running royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the years ended July 31, 2017, 2016 and 2015, the Company recorded royalty income under the agreement of approximately $1,205, $1,521 and $2,495 respectively, which is included in the Life Sciences segment.